The Galectin Intelligence Platform.
From Human Pathway Perturbation to Clinical Precision
Built on real-world patient biomarker and clinical data from Galectin-3 modulation, the platform converts every trial readout into sharper predictive models, leaner clinical designs, and new therapeutic targets.
A Self-Reinforcing Clinical & AI Flywheel
Every clinical readout sharpens our predictive models, refines trial design, and uncovers next-generation targets.
Drug
Human data
Better trials and new targets
AI
How Human Perturbation Data Drives Every Trial
Rather than training on synthetic assumptions, our computational stack ingests multi-dimensional clinical and biomarker readouts from TB006-treated patients to sharpen trial execution and antibody discovery.
End-to-End Computational Architecture
Multi-Modal Clinical Readouts
Longitudinal plasma Galectin-3 kinetics (~9x target engagement), PK/PD profiles, inflammatory biomarker panels, and clinical cognitive/motor endpoints across neurodegenerative cohorts.
Trajectory & Subgroup Analytics
Baseline covariate modeling, untreated disease-trajectory forecasting, and multi-dimensional responder clustering built on real human pathway perturbation.
Trial & Pipeline Execution
Prognostic covariate adjustment for leaner Phase 2/3 trials, biomarker-guided inclusion criteria, and epitope prioritization for next-generation antibodies.
Prognostic digital twins
For each trial participant, the platform models the disease trajectory they would most likely follow without treatment based on baseline clinical and biomarker covariates. Incorporating these prognostic scores reduces unexplained outcome variance—enabling smaller sample sizes and higher statistical confidence under regulatory-qualified prognostic frameworks.
Responder enrichment
Neuroinflammatory and neurodegenerative patients do not respond uniformly. By mining longitudinal human datasets from completed Phase 1b/2a studies and ongoing Phase 2 cohorts, the platform identifies baseline biomarker and clinical signatures linked to stronger Gal-3 target engagement and clinical benefit—preventing signal dilution in subsequent trials.
Human-first target discovery
Pharmacological neutralization of Galectin-3 in people provides a direct, in vivo readout of how the pathway regulates chronic inflammation and protein aggregation in human biology. The platform analyzes downstream biomarker shifts to guide affinity and epitope engineering for next-generation Gal-3 antibodies and uncover adjacent pathway targets.
What the Platform Is Not
TrueBinding treats artificial intelligence as an instrument for rigorous biology—never a substitute for experimental or clinical proof.
Not a replacement for wet-lab validation
Computational predictions generate hypotheses, not proof. No AI-derived antibody candidate or target insight advances without rigorous biochemical, cellular, and in vivo validation.
Not a promise beyond the data
We do not treat algorithms as black-box oracles or extrapolate past what human biology supports. Every prognostic model and responder signature must be earned through reproducible clinical readouts.
Not unmeasured efficiency claims
We do not publish hypothetical timeline cuts or speculative cost-reduction projections. Operational and trial-design gains are reported only after they are empirically measured in prospective studies.
George Hong
Founder & Chief Executive Officer
Why a Computer Scientist Founded a Biotech
“Drug development’s bottleneck is no longer chemistry — it is knowing which patients, which trials, and which targets. The company is built the way a data company is built: the drug generates the data, and the data improves the drug.”
George Hong founded TrueBinding in 2016 on that simple observation. That closed-loop architecture is the Galectin Intelligence Platform, and it is the reason a computer scientist built a clinical-stage biotechnology company.
Alongside leading TrueBinding, he serves as Chief Executive Officer of Wangsu Technology (SZSE: 300017), where he is spearheading the company’s strategic transformation into large-scale AI infrastructure for AI models—bringing deep systems-engineering and data-platform discipline directly into therapeutic development.